AbbVie, Enanta drug shows potential in hep C genotype 4 patients

Nov 11 (Reuters) - AbbVie Inc said its experimental drug that treats genotype 4 hepatitis C showed high response rates in a mid-stage study in patients who have been considered difficult to treat.